CJC-1295 with DAC 2 mg

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic growth hormone-releasing hormone (GHRH) analog designed to stimulate the pituitary gland to increase natural growth hormone secretion. The DAC component extends its half-life, allowing for prolonged activity and sustained GH release over time.

How It Works

CJC-1295 mimics natural GHRH, binding to receptors in the pituitary gland and stimulating growth hormone release. The DAC modification enables the compound to bind to plasma proteins, significantly extending its duration of action. This results in more stable and prolonged elevation of growth hormone and downstream IGF-1 levels, which may support anabolic and metabolic processes.

Dosage Overview

CJC-1295 with DAC is typically administered via subcutaneous injection. A common dosing range is 1–2 mg per week, often given once or twice weekly due to its extended half-life. It is frequently used in cycles and may be combined with other peptides such as GHRP or Ipamorelin depending on the intended goal. Dosing should be adjusted based on individual response and guidance from a qualified professional.

Potential Benefits

CJC-1295 with DAC is associated with increased growth hormone and IGF-1 levels, which may contribute to improved muscle growth, fat loss, recovery, and sleep quality. It may also support joint health, collagen production, skin elasticity, and overall vitality, making it popular in both performance and wellness contexts.

Side Effects and Considerations

Possible side effects include mild injection site reactions, headaches, water retention, and tingling sensations. In some cases, prolonged elevation of growth hormone levels may contribute to insulin resistance, joint discomfort, or carpal tunnel-like symptoms. Careful dosing and monitoring are recommended to reduce potential risks associated with long-term hormonal elevation.